Page 4 - Medical Affairs News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Harnessing small molecules to treat chronic inflammatory diseases

Learn how Abivax's small molecule treatment could benefit UC patients and why these drugs hold promise to treat autoimmune diseases.

United statesSheldon sloanRush medical collegeGlobal medical affairs leaderUniversity of pennsylvaniaArena pharmaceuticalsProgram lead for velsipityChief medical officerBiotech abivaxModified mayo scoreProgram leadMedical affairs

Blue Earth Diagnostics Highlights Presentations on POSLUMA (Flotufolastat F 18), Axumin (Fluciclovine F 18) and Investigational 18F-Flotufolastat/18F-rhPSMA-7 at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced upcoming presentations by its collaborators

United kingdomUnited statesMarkt schwabenDavide gaudenSean collinsClare gidleyPriscilla harlanIsabel rauscherIsmaheel lawalNadine mallakElizabeth hawkMike beyerTodd cohenScience universityBracco groupGeorgetown university hospital

Veristat Appoints Gabriela Rosu, M D , to Lead Growing Medical Affairs Team

To support sponsors around the globe bringing novel treatments to patients Veristat, the Science-First Full Service CRO and Consultancy, is pleased to announce that Gabriela Rosu, M.D., has joined

United statesLaurenl brennanPatrick flanaganGabriela rosuAmerican society for clinical oncologyGlobal medical affairsAmerican society of clinical oncologyFirst full serviceEuropean society for medical oncologyGlobal medical affairs at veristatVeristat medical affairsGlobal medical affairs veristat photoScience first full serviceSenior directorGlobal medicalGlobal medical affairs veristat

New Cohort Study Data Shows Baxter s Expanded Hemodialysis – Known as HDx Therapy – Is Associated With Approximately 25% Lower Mortality Rate for up to Four Years

New Cohort Study Data Shows Baxter s Expanded Hemodialysis – Known as HDx Therapy – Is Associated With Approximately 25% Lower Mortality Rate for up to Four Years
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Baxter theranovaBaxter hdxUrol nephrolPeter rutherfordEuropean uremic toxin work groupBaxter renal care services centersBaxter international incEuropean renal associationBaxter internationalEuropean renal association dialysisTransplant associationRenal care services centersProfessor peter rutherfordMedical affairsKidney careExpanded hemodialysis therapy

Baxter: Four-year Study Indicates Approx 25% Lower Mortality With Use Of Theranova Dialyzer

Baxter International (BAX) announced new data showing expanded hemodialysis, known as HDx therapy, enabled by Theranova dialyzer, was associated with an approximately 25% lower all-cause mortality risk for up to four years when compared to high-flux hemodialysis.

Peter rutherfordBaxter theranovaMore such health newsBaxter renal care services centersBaxter internationalRenal care services centersMedical affairsKidney care